Targets › TROP2
22 programs from 17 companies in 92 trials: 35 Phase 2, 35 Phase 1, 22 Phase 3; Oncology, Gastroenterology, Genitourinary; next expected readout Nov 2026.
May function as a growth factor receptor. (UniProt, P09758)
Open in Phaseline: the race on TROP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sichuan Baili Pharmaceutical | BL-B01D1 Anti-TROP2 antibody-drug conjugate | TROP-2, TROP2, TACSTD2 | Phase 3 | Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Non-small Cell Lung Cancer; Epithelial Ovarian Cancer … | Nov 2026 |
| GSK | Mocertatug Rezetecan (Mo-Rez) TROP2-directed antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload | TROP2 | Phase 3 | Neoplasms, Endometrial; Ovarian Neoplasms; Tumours, Gynecological; Solid Tumors | Jun 2027 |
| GSK | Risvutatug Rezetecan (GSK5764227) anti-B7-H3 antibody-drug conjugate | TROP2, CD276 | Phase 3 | Neoplasms, Lung; Neoplasms, Prostate; Neoplasms; Gastrointestinal Neoplasms | Aug 2027 |
| RenJi Hospital | [18F]F-RESCA-RCCB6 Trop2/HER2-targeted PET imaging agent | CD70, TROP2, TACSTD2, ERBB2 | Phase 2 | Urologic Neoplasms; Renal Cancer; Solid Tumor; Breast Cancer | Nov 2026 |
| RenJi Hospital | [68Ga]Ga-NOTA-R8B4 CD70-targeted immunoPET imaging agent | CD70, TROP2 | Phase 2 | Renal Cancer; Solid Tumor | Dec 2026 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trop2-ADC anti-TROP2 antibody-drug conjugate | TROP2 | Phase 2 | Metastatic Triple-negative Breast Cancer | Apr 2027 |
| Akeso | AK146D1 Anti-Trop2/Nectin4 bispecific antibody-drug conjugate | TROP2, NECTIN4 | Phase 2 | Advanced Non Small Cell Lung Cancer (NSCLC); Advanced Breast Cancer; Advanced Solid Tumors | May 2027 |
| Shanghai Chest Hospital | Sacituzumab Tirumotecan (SKB264) TROP2-directed antibody-drug conjugate | TROP2 | Phase 2 | Esophageal Squamous Cell Carcinoma | Dec 2027 |
| Fudan University | TROP2 ADC TROP2-targeted antibody-drug conjugate | TROP2 | Phase 2 | Triple-negative Breast Cancer | Dec 2027 |
| Shanghai Jiao Tong University School of Medicine | Sacituzumab Tirumotecan (Sac-TMT) Anti-TROP2 antibody-drug conjugate (ADC) with SN-38 payload | TROP2 | Phase 2 | Breast Cancer | Aug 2028 |
| Bio-Thera Solutions | BAT8008 for Injection Recombinant humanized anti-Trop2 monoclonal antibody conjugated to exatecan | TROP2 | Phase 1 | Advanced Solid Tumors | Nov 2026 |
| LigaChem Biosciences | LCB84 TROP2-directed antibody-drug conjugate with monomethyl auristatin E (MMAE) | TROP2 | Phase 1 | Advanced Solid Tumors | Jan 2027 |
| Beijing Biotech | EB-NK-MF CAR-NK cells Dual-targeting CAR-NK cells engineered to target Mesothelin and Folate Receptor alpha (wit | MSLN, FOLR1, MUC16, TROP2 | Phase 1 | Advanced Solid Tumors; Epithelial Ovarian Cancer | Feb 2027 |
| Mabwell (Shanghai) Bioscience | bulumtatug fuvedotin anti-TROP2 antibody-drug conjugate | TROP2 | Phase 1 | Triple Negative Breast Cancer | May 2027 |
| OBI Pharma | OBI-992 Anti-TROP2 antibody-drug conjugate with exatecan payload | TROP2 | Phase 1 | Advanced Solid Tumor | Jun 2027 |
| M.D. Anderson Cancer Center | TROP2-CAR-NK Cells TROP2-directed CAR-NK cells with IL-15 transduction | TROP2 | Phase 1 | Pancreatic Cancer; Colorectal Cancer; Solid Tumors | Oct 2027 |
| M.D. Anderson Cancer Center | Cytokine-treated Veto Cells CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel | IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2 | Phase 1 | Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal Cancer | Dec 2027 |
| M.D. Anderson Cancer Center | TROP2 CAR/IL-15 TGFBR2 KO NK cells CAR-T cell therapy targeting TROP2 with IL-15 transduction and TGFBR2 knockout in cord blo | TROP2, IL15, TGFBR2 | Phase 1 | Head and Neck Cancer | Dec 2027 |
| Eastern Hepatobiliary Surgery Hospital | Super Hi-TCR-T cells Multi-target TCR-engineered T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP | PVRL4, KLRC1, TROP2, B7H3, GPC3 | Phase 1 | Advanced Hepatocellular Carcinoma (HCC) | Jan 2028 |
| M.D. Anderson Cancer Center | TGFBR2 KO CAR27/IL-15 NK cells TROP2-targeted CAR-NK cells with IL-15 co-expression and TGFBR2 knockout | TROP2, TGFBR2, IL15 | Phase 1 | Gastric Cancer, Metastatic; Lymphoid | Jul 2028 |
| MacroGenics | vobramitamab tavatecan anti-TROP2 antibody-drug conjugate with SN-38 payload | TROP2 | Phase 1 | Advanced Solid Tumor | Oct 2028 |
| Astellas | ASP2998 anti-TROP2 antibody-drug conjugate | TROP2 | Phase 1 | Locally Advanced or Metastatic Malignant Solid Tumors | Jun 2029 |
Non-small Cell Lung Cancer (8) Advanced Solid Tumors (6) Breast Cancer (5) Epithelial Ovarian Cancer (3) Esophageal Squamous Cell Carcinoma (3) Urothelial Carcinoma (3) Renal Cancer (3) Ovarian Neoplasms (3) Small Cell Lung Cancer (2) Extensive-stage Small-cell Lung Cancer (2) Triple-negative Breast Cancer (2) Cervical Cancer (2)
mixed (10), small molecule (6), antibody (5), other (1)
M.D. Anderson Cancer Center (4) GSK (2) RenJi Hospital (2) Sichuan Baili Pharmaceutical (1) Astellas (1) Fudan University (1) Shanghai Jiao Tong University School of Medicine (1) Beijing Biotech (1) Akeso (1) MacroGenics (1) OBI Pharma (1) Mabwell (Shanghai) Bioscience (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Shanghai Chest Hospital (1) Eastern Hepatobiliary Surgery Hospital (1) Bio-Thera Solutions (1) LigaChem Biosciences (1)
TGFBR2 (3) TACSTD2 (2) IL15 (2) CD70 (2) TROP-2 (1) CD276 (1) MSLN (1) FOLR1 (1) MUC16 (1) ERBB2 (1) NECTIN4 (1) IL13RA1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.